Down-regulation and deficient expression of PPARα are associated with the development of NASH, and treatment with agonist for PPARα prevents and inhibits the development of NAFLD[21,22]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.